-
1
-
-
80052483131
-
Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors
-
1:CAS:528:DC%2BC3MXhtFSmtLnP 21670084 10.1158/1078-0432.CCR-10-2616
-
Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546-52.
-
(2011)
Clin Cancer Res
, vol.17
, Issue.17
, pp. 5546-5552
-
-
Montero, J.C.1
Seoane, S.2
Ocana, A.3
Pandiella, A.4
-
2
-
-
70349758510
-
Src kinases as therapeutic targets for cancer
-
19787002 10.1038/nrclinonc.2009.129
-
Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6(10):587-95.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, Issue.10
, pp. 587-595
-
-
Kim, L.C.1
Song, L.2
Haura, E.B.3
-
3
-
-
2942618768
-
A renaissance for SRC
-
1:CAS:528:DC%2BD2cXksVaisbo%3D 15170449 10.1038/nrc1366
-
Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470-80.
-
(2004)
Nat Rev Cancer
, vol.4
, Issue.6
, pp. 470-480
-
-
Yeatman, T.J.1
-
4
-
-
0038386613
-
Src family kinases in tumor progression and metastasis
-
1:CAS:528:DC%2BD3sXjslyiu74%3D 12884910 10.1023/A:1023772912750
-
Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22(4):337-58.
-
(2003)
Cancer Metastasis Rev
, vol.22
, Issue.4
, pp. 337-358
-
-
Summy, J.M.1
Gallick, G.E.2
-
5
-
-
33847728182
-
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
-
1:CAS:528:DC%2BD2sXhvVWqsbs%3D 17308097 10.1158/0008-5472.CAN-06-2027
-
Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res. 2007;67(4):1580-8.
-
(2007)
Cancer Res
, vol.67
, Issue.4
, pp. 1580-1588
-
-
Jallal, H.1
Valentino, M.L.2
Chen, G.3
Boschelli, F.4
Ali, S.5
Rabbani, S.A.6
-
6
-
-
33846261886
-
The Src signaling pathway: A potential target in melanoma and other malignancies
-
1:CAS:528:DC%2BD28Xht1yisL7M 17150037 10.1517/14728222.11.1.91
-
Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007;11(1):91-100.
-
(2007)
Expert Opin Ther Targets
, vol.11
, Issue.1
, pp. 91-100
-
-
Homsi, J.1
Cubitt, C.2
Daud, A.3
-
7
-
-
1642551021
-
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells
-
1:CAS:528:DC%2BD2cXivFSqsrY%3D 15073106 10.1158/1078-0432.CCR-1183-3
-
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004;10(7):2307-18.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.7
, pp. 2307-2318
-
-
Duxbury, M.S.1
Ito, H.2
Zinner, M.J.3
Ashley, S.W.4
Whang, E.E.5
-
8
-
-
0037784223
-
Pp60c-src activation in lung adenocarcinoma
-
1:CAS:528:DC%2BD3sXkvVWjsrw%3D 12826049 10.1016/S0959-8049(03)00276-4
-
Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer. 2003;39(10):1447-55.
-
(2003)
Eur J Cancer
, vol.39
, Issue.10
, pp. 1447-1455
-
-
Masaki, T.1
Igarashi, K.2
Tokuda, M.3
-
9
-
-
0037150728
-
Src in cancer: Deregulation and consequences for cell behaviour
-
1:CAS:528:DC%2BD38XjvVeitLs%3D 12020799
-
Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 2002;1602(2):114-30.
-
(2002)
Biochim Biophys Acta
, vol.1602
, Issue.2
, pp. 114-130
-
-
Frame, M.C.1
-
10
-
-
0037080135
-
Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
-
11900220 10.1002/cncr.10221
-
Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002;94(2):344-51.
-
(2002)
Cancer
, vol.94
, Issue.2
, pp. 344-351
-
-
Aligayer, H.1
Boyd, D.D.2
Heiss, M.M.3
Abdalla, E.K.4
Curley, S.A.5
Gallick, G.E.6
-
11
-
-
19944428353
-
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
-
1:CAS:528:DC%2BD2cXhtVKrsrnI 15615512 10.1021/jm049486a
-
Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658-61.
-
(2004)
J Med Chem
, vol.47
, Issue.27
, pp. 6658-6661
-
-
Lombardo, L.J.1
Lee, F.Y.2
Chen, P.3
-
12
-
-
79955500900
-
A phase 2 trial of dasatinib in advanced melanoma
-
1:CAS:528:DC%2BC3MXltFyms7g%3D 3116034 21523734 10.1002/cncr.25766
-
Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011;117(10):2202-8.
-
(2011)
Cancer
, vol.117
, Issue.10
, pp. 2202-2208
-
-
Kluger, H.M.1
Dudek, A.Z.2
McCann, C.3
-
13
-
-
33749021085
-
Somatic activation of KIT in distinct subtypes of melanoma
-
1:CAS:528:DC%2BD28XhtVGju7bM 16908931 10.1200/JCO.2006.06.2984
-
Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-6.
-
(2006)
J Clin Oncol
, vol.24
, Issue.26
, pp. 4340-4346
-
-
Curtin, J.A.1
Busam, K.2
Pinkel, D.3
Bastian, B.C.4
-
14
-
-
50249141632
-
Phase II trial of imatinib mesylate in patients with metastatic melanoma
-
1:CAS:528:DC%2BD1cXhtVGgtb%2FK 2528157 18728664 10.1038/sj.bjc.6604482
-
Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99(5):734-40.
-
(2008)
Br J Cancer
, vol.99
, Issue.5
, pp. 734-740
-
-
Kim, K.B.1
Eton, O.2
Davis, D.W.3
-
15
-
-
33646268037
-
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy
-
1:CAS:528:DC%2BD28XkvFGhs7g%3D 16565971 10.1002/cncr.21834
-
Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006;106(9):2005-11.
-
(2006)
Cancer
, vol.106
, Issue.9
, pp. 2005-2011
-
-
Wyman, K.1
Atkins, M.B.2
Prieto, V.3
-
16
-
-
21044460131
-
Lack of clinical efficacy of imatinib in metastatic melanoma
-
1:CAS:528:DC%2BD2MXjsVSjtro%3D 2362005 15846297 10.1038/sj.bjc.6602529
-
Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92(8):1398-405.
-
(2005)
Br J Cancer
, vol.92
, Issue.8
, pp. 1398-1405
-
-
Ugurel, S.1
Hildenbrand, R.2
Zimpfer, A.3
-
17
-
-
79960708519
-
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification
-
1:CAS:528:DC%2BC3MXhtVOqsLnJ 21690468 10.1200/JCO.2010.33.9275
-
Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-9.
-
(2011)
J Clin Oncol
, vol.29
, Issue.21
, pp. 2904-2909
-
-
Guo, J.1
Si, L.2
Kong, Y.3
-
18
-
-
79958066836
-
KIT as a therapeutic target in metastatic melanoma
-
1:CAS:528:DC%2BC3MXntlOnsrY%3D 21642685 10.1001/jama.2011.746
-
Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.
-
(2011)
JAMA
, vol.305
, Issue.22
, pp. 2327-2334
-
-
Carvajal, R.D.1
Antonescu, C.R.2
Wolchok, J.D.3
-
19
-
-
33748340618
-
A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity
-
16791448 10.1245/ASO.2006.05.003
-
Brady MS, Brown K, Patel A, Fisher C, Marx W. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13(8):1123-9.
-
(2006)
Ann Surg Oncol
, vol.13
, Issue.8
, pp. 1123-1129
-
-
Brady, M.S.1
Brown, K.2
Patel, A.3
Fisher, C.4
Marx, W.5
-
20
-
-
3843113670
-
Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years?
-
1:CAS:528:DC%2BD2cXmt1OitL0%3D 15288283 10.1016/j.ejca.2004.04.030
-
Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40(12):1825-36.
-
(2004)
Eur J Cancer
, vol.40
, Issue.12
, pp. 1825-1836
-
-
Eggermont, A.M.1
Kirkwood, J.M.2
-
21
-
-
0036210893
-
Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma
-
11888868
-
Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9(2):127-36.
-
(2002)
Ann Surg Oncol
, vol.9
, Issue.2
, pp. 127-136
-
-
Lindner, P.1
Doubrovsky, A.2
Kam, P.C.3
Thompson, J.F.4
-
22
-
-
77950827393
-
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma
-
1:CAS:528:DC%2BC3cXktlCqtro%3D 20371714 10.1158/1535-7163.MCT-09-0764
-
Augustine CK, Jung SH, Sohn I, et al. Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther. 2010;9(4):779-90.
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.4
, pp. 779-790
-
-
Augustine, C.K.1
Jung, S.H.2
Sohn, I.3
-
23
-
-
77954572289
-
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy
-
1:CAS:528:DC%2BC3cXhtFertbfM 20571072 10.1158/1535-7163.MCT-10-0073
-
Augustine CK, Toshimitsu H, Jung SH, et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther. 2010;9(7):2090-101.
-
(2010)
Mol Cancer Ther
, vol.9
, Issue.7
, pp. 2090-2101
-
-
Augustine, C.K.1
Toshimitsu, H.2
Jung, S.H.3
-
24
-
-
77954951941
-
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma
-
20182810 10.1245/s10434-010-0971-x
-
Toshimitsu H, Yoshimoto Y, Augustine CK, et al. Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma. Ann Surg Oncol. 2010;17(8):2247-54.
-
(2010)
Ann Surg Oncol
, vol.17
, Issue.8
, pp. 2247-2254
-
-
Toshimitsu, H.1
Yoshimoto, Y.2
Augustine, C.K.3
-
25
-
-
34250740979
-
Defining regional infusion treatment strategies for extremity melanoma: Comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents
-
1:CAS:528:DC%2BD2sXotFalt7Y%3D 17483437 10.1158/1535-7163.MCT-06-0718
-
Yoshimoto Y, Augustine CK, Yoo JS, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther. 2007;6(5):1492-500.
-
(2007)
Mol Cancer Ther
, vol.6
, Issue.5
, pp. 1492-1500
-
-
Yoshimoto, Y.1
Augustine, C.K.2
Yoo, J.S.3
-
26
-
-
33645474059
-
Modulation of chemotherapy resistance in regional therapy: A novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine
-
1:CAS:528:DC%2BD28Xitl2lu7s%3D 16546988 10.1158/1535-7163.MCT-05-0098
-
Ueno T, Ko SH, Grubbs E, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther. 2006;5(3):732-8.
-
(2006)
Mol Cancer Ther
, vol.5
, Issue.3
, pp. 732-738
-
-
Ueno, T.1
Ko, S.H.2
Grubbs, E.3
-
27
-
-
68849093078
-
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
-
1:CAS:528:DC%2BD1MXpvFCnur8%3D 3346953 19671763 10.1158/1535-7163.MCT-09- 0459
-
Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009;8(8):2079-85.
-
(2009)
Mol Cancer Ther
, vol.8
, Issue.8
, pp. 2079-2085
-
-
Woodman, S.E.1
Trent, J.C.2
Stemke-Hale, K.3
-
28
-
-
4444338326
-
SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling
-
1:CAS:528:DC%2BD2cXnslCrsbw%3D 515031 15340073 10.1128/MCB.24.18.8113- 8133.2004
-
Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO. SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol. 2004;24(18):8113-33.
-
(2004)
Mol Cell Biol
, vol.24
, Issue.18
, pp. 8113-8133
-
-
Westhoff, M.A.1
Serrels, B.2
Fincham, V.J.3
Frame, M.C.4
Carragher, N.O.5
-
29
-
-
8544245666
-
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma
-
1:CAS:528:DC%2BD2cXpsl2hsrs%3D 15546565 10.1016/j.amjsurg.2004.07.014
-
Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS. Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. Am J Surg. 2004;188(5):532-7.
-
(2004)
Am J Surg
, vol.188
, Issue.5
, pp. 532-537
-
-
Ueno, T.1
Ko, S.H.2
Grubbs, E.3
Pruitt, S.K.4
Friedman, H.S.5
Tyler, D.S.6
-
30
-
-
7944236785
-
Src family kinases, key regulators of signal transduction
-
1:CAS:528:DC%2BD2cXosFylur8%3D 15489908 10.1038/sj.onc.1208160
-
Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906-9.
-
(2004)
Oncogene
, vol.23
, Issue.48
, pp. 7906-7909
-
-
Parsons, S.J.1
Parsons, J.T.2
-
31
-
-
84855345509
-
Phase i clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
-
3251861 22127285 10.1038/bjc.2011.514
-
Algazi AP, Weber JS, Andrews SC, et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2011;106:85-91.
-
(2011)
Br J Cancer
, vol.106
, pp. 85-91
-
-
Algazi, A.P.1
Weber, J.S.2
Andrews, S.C.3
-
32
-
-
77954216079
-
Targeting KIT in melanoma: A paradigm of molecular medicine and targeted therapeutics
-
1:CAS:528:DC%2BC3cXosV2isrc%3D 20457136 10.1016/j.bcp.2010.04.032
-
Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80(5):568-74.
-
(2010)
Biochem Pharmacol
, vol.80
, Issue.5
, pp. 568-574
-
-
Woodman, S.E.1
Davies, M.A.2
-
33
-
-
54349085882
-
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
-
2569026 18823558 10.1186/1479-5876-6-53
-
Eustace AJ, Crown J, Clynes M, O'Donovan N. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med. 2008;6:53.
-
(2008)
J Transl Med
, vol.6
, pp. 53
-
-
Eustace, A.J.1
Crown, J.2
Clynes, M.3
O'Donovan, N.4
-
34
-
-
67849128649
-
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
-
1:CAS:528:DC%2BD1MXlslGis7k%3D 19434004 10.1097/CMR.0b013e328304974c
-
Homsi J, Cubitt CL, Zhang S, et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009;19(3):167-75.
-
(2009)
Melanoma Res
, vol.19
, Issue.3
, pp. 167-175
-
-
Homsi, J.1
Cubitt, C.L.2
Zhang, S.3
-
35
-
-
84862561507
-
Bevacizumab-induced alterations in vascular permeability and drug delivery: A novel approach to augment regional chemotherapy for in-transit melanoma
-
1:CAS:528:DC%2BC38Xos1Olurk%3D 3618183 22496203 10.1158/1078-0432.CCR-11- 3000
-
Turley RS, Fontanella AN, Padussis JC, et al. Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. Clin Cancer Res. 2012;18(12):3328-39.
-
(2012)
Clin Cancer Res
, vol.18
, Issue.12
, pp. 3328-3339
-
-
Turley, R.S.1
Fontanella, A.N.2
Padussis, J.C.3
-
36
-
-
0242333907
-
Inactivation of Src family kinases inhibits angiogenesis in vivo: Implications for a mechanism involving organization of the actin cytoskeleton
-
1:CAS:528:DC%2BD3sXos1Citrk%3D 14597409 10.1016/S0014-4827(03)00374-4
-
Kilarski WW, Jura N, Gerwins P. Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res. 2003;291(1):70-82.
-
(2003)
Exp Cell Res
, vol.291
, Issue.1
, pp. 70-82
-
-
Kilarski, W.W.1
Jura, N.2
Gerwins, P.3
-
37
-
-
37049036163
-
Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability
-
1:CAS:528:DC%2BD2sXhsVeis7%2FF 2096609 17928406 10.1091/mbc.E07-01-0004
-
Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell. 2007;18(12):5014-23.
-
(2007)
Mol Biol Cell
, vol.18
, Issue.12
, pp. 5014-5023
-
-
Petreaca, M.L.1
Yao, M.2
Liu, Y.3
Defea, K.4
Martins-Green, M.5
-
39
-
-
42949128595
-
Major response to imatinib mesylate in KIT-mutated melanoma
-
1:CAS:528:DC%2BD1cXlvFaqs7Y%3D 18421059 10.1200/JCO.2007.14.0707
-
Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;26(12):2046-51.
-
(2008)
J Clin Oncol
, vol.26
, Issue.12
, pp. 2046-2051
-
-
Hodi, F.S.1
Friedlander, P.2
Corless, C.L.3
-
40
-
-
0032483575
-
A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth
-
1:CAS:528:DyaK1cXmtVWksr0%3D 9741627 10.1016/S0092-8674(00)81604-9
-
Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 1998;94(5):625-34.
-
(1998)
Cell
, vol.94
, Issue.5
, pp. 625-634
-
-
Wary, K.K.1
Mariotti, A.2
Zurzolo, C.3
Giancotti, F.G.4
-
41
-
-
79952598575
-
In vitro studies of dasatinib, its targets and predictors of sensitivity
-
21320292 10.1111/j.1755-148X.2011.00835.x
-
Jilaveanu LB, Zito CR, Aziz SA, et al. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res. 2011;24(2):386-9.
-
(2011)
Pigment Cell Melanoma Res
, vol.24
, Issue.2
, pp. 386-389
-
-
Jilaveanu, L.B.1
Zito, C.R.2
Aziz, S.A.3
-
42
-
-
48149092966
-
Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion
-
18528730 10.1245/s10434-008-9988-9
-
Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195-205.
-
(2008)
Ann Surg Oncol
, vol.15
, Issue.8
, pp. 2195-2205
-
-
Beasley, G.M.1
Petersen, R.P.2
Yoo, J.3
-
43
-
-
45549085493
-
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment
-
1:CAS:528:DC%2BD1cXlvVOitbk%3D 18483261 10.1158/0008-5472.CAN-07-5949
-
Augustine CK, Yoshimoto Y, Gupta M, et al. Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res. 2008;68(10):3777-84.
-
(2008)
Cancer Res
, vol.68
, Issue.10
, pp. 3777-3784
-
-
Augustine, C.K.1
Yoshimoto, Y.2
Gupta, M.3
-
44
-
-
0036447366
-
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
-
1:CAS:528:DC%2BD38XhtFCltbs%3D 11846617 10.1006/phrs.2001.0935
-
Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res. 2002;45(2):73-85.
-
(2002)
Pharmacol Res
, vol.45
, Issue.2
, pp. 73-85
-
-
Tentori, L.1
Portarena, I.2
Graziani, G.3
-
45
-
-
0036733355
-
The therapeutic potential of poly(ADP-ribose) polymerase inhibitors
-
1:CAS:528:DC%2BD38XotVSmsr8%3D 12223530 10.1124/pr.54.3.375
-
Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3):375-429.
-
(2002)
Pharmacol Rev
, vol.54
, Issue.3
, pp. 375-429
-
-
Virag, L.1
Szabo, C.2
|